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Circulating Secretin Activates Supraoptic Nucleus
Oxytocin and Vasopressin Neurons via Noradrenergic
Pathways in the Rat
Sathya Velmurugan, Paula J. Brunton, Gareth Leng, and John A. Russell
Centre for Integrative Physiology, School of Biomedical Sciences, College of Medicine and Veterinary
Medicine, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom
Secretin is a 27-amino acid brain-gut peptide from duodenal S-cells. We tested the effects of
systemic administrationof secretin to simulate its postprandial releaseonneuroendocrineneurons
of the supraoptic nucleus (SON) in urethane-anesthetized female rats. Secretin dose-dependently
increased the firing rate of oxytocin neurons, more potently than cholecystokinin, and dose-
dependently increased plasma oxytocin concentration. The effect of secretin on SON vasopressin
neuronswas alsopredominantly excitatory, in contrast to the inhibitory actions of cholecystokinin.
To explore the involvement of noradrenergic inputs in secretin-induced excitation, benoxathian,
an 1-adrenoceptor antagonist, was infused intracerebroventricularly. Benoxathian intracerebro-
ventricular infusion blocked the excitation by secretin of both oxytocin and vasopressin neurons.
To test the role of local noradrenaline release in the SON, benoxathianwasmicrodialyzed onto the
SON. The basal firing rate of oxytocin neurons was slightly reduced and the secretin-induced
excitation was attenuated during benoxathianmicrodialysis. Hence, noradrenergic pathways me-
diate the excitation by systemic secretin of oxytocin neurons via 1-adrenoceptors in the SON. As
both systemic secretin and oxytocin are involved in regulating gastrointestinal functions and na-
triuresis, systemically released secretin might act partly through oxytocin. (Endocrinology 151:
2681–2688, 2010)
Secretin, a peptide hormone synthesized by the duode-nal S-cells, is secreted into the systemic circulation
when acidic contents enter the duodenum from the stom-
ach. Secretin acts locally to neutralize this acidity by stim-
ulating the secretionof fluid andbicarbonate ions fromthe
pancreas (1, 2), and also promotes the secretion of bile
from the liver. In addition, secretin may also signal to the
CNS, as peripheral injections of secretin result in Fos ex-
pression in specific brain areas (3, 4), including the su-
praoptic nucleus (SON) of the hypothalamus (4), which
contains the cell bodies of magnocellular neuroendocrine
neurons that project to the posterior pituitary gland to
secrete oxytocin and vasopressin. Intracerebroventricular
(i.c.v.) administration of secretin also increases Fos ex-
pression in SON neurons and increases peripheral secre-
tion of oxytocin and vasopressin, and secretin receptors
are found in the SON and the magnocellular area of the
paraventricular nucleus (5). However, secretin also acti-
vates vagal primary afferent neurons (6).
Many gut-derived factors are now known to signal to
the hypothalamus, either directly or indirectly via vagal
afferents. To test the hypothesis that circulating secretin
has a physiological action on the hypothalamus, we used
low doses of systemic secretin (1g/rat) (7), and studied
their effects on the electrical activity of neuroendocrine neu-
rons in the SON in vivo. We compared the responses to se-
cretin with responses to cholecystokinin (CCK), a function-
ally similar peptide (8). When administered iv, CCK excites
oxytocin neurons and either inhibits or does not affect the
firing rate of SON vasopressin neurons (9–11).
The SON receives excitatory noradrenergic inputs
from the nucleus tractus solitarii (NTS) (12). The activa-
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tion of1 adrenergic receptors induces release of oxytocin
and vasopressin from hypothalamic explants (13). To in-
vestigate the hypothesis that excitatory noradrenergic
pathways mediate secretin-induced responses in SON
neurons via 1 adrenergic receptors, the effect on the re-
sponses to secretin of i.c.v. infusion and microdialysis ap-
plication to the SON of benoxathian hydrochloride (a
competitive 1 adrenergic antagonist) was also studied.
Materials and Methods
Animals
Adult (10 wk old) female Sprague Dawley rats of 200–300
g body weight were obtained from the colony maintained at the
University of Edinburgh. The rats were housed under a 12-h
light, 12-hdark cycle (lights onat0700h)with free access to food
and water. Temperature was maintained at 19–23 C and hu-
midity at 55  10%. All procedures were performed in accor-
dancewith the currentUnitedKingdomHomeOffice regulations
under the Animals (Scientific Procedures) Act 1986.
In vivo electrophysiology
Anesthesiawas induced by brief exposure to halothane vapor
in an anesthetic chamber, followed by ip injection of urethane
(ethyl carbamate; 25% wt/vol; 1.25 g/kg). The left femoral vein
was cannulated for iv drug administration and connected to a
syringe containing 0.9% NaCl. An endotracheal tube was in-
serted into the trachea to keep the airway patent. Using a ventral
transpharyngeal surgical procedure (14), the SON and neural
stalk were exposed. A glass recording microelectrode with a tip
diameter of approximately 1 m filled with 0.15 M NaCl was
lowered into the SON under visual control. Signals were ampli-
fied and 50 Hz noise and harmonics were eliminated from the
signal (Hum Bug, Quest Scientific, Vancouver, British Colum-
bia, Canada). A Digitimer D130 spike processor was used to
detect spikes, and the raw signal and the detected spikes were
passed through an interface (CED1401; Cambridge Electronic
Design, Cambridge, UK) to a personal computer for analysis
using Spike2 software (CED). In each rat, between one and three
neurons were recorded and tested with injections of secretin. At
the end of each experiment, rats were killed by an overdose of
sodium pentobarbitone (60mg/kg; iv), and correct placement of
any i.c.v. cannula confirmed.
SON neurons were antidromically identified as projecting to
theposteriorpituitaryby electrical stimulationof theneural stalk
(matched biphasic pulses, 1 mA for 1 msec, via a bipolar stim-
ulating electrode). Oxytocin neurons were differentiated from
vasopressin neurons by their firing pattern; many vasopressin
cells fire “phasically,” i.e., in prolonged bursts of action poten-
tials separated by long silent phases.However, other vasopressin
neurons fire continuously, and oxytocin neurons were differen-
tiated from these by the shape of their interspike interval histo-
gramandhazard function (15). Foroxytocinneurons, butnot for
vasopressin neurons, the descending tails of the interspike inter-
val distributions can be fitted well using a single negative expo-
nential (16). Hazard functions plot how the excitability of a cell
changes with time after it has fired a spike. Specifically, hazard
functions show the probability of occurrence of a spike as a
function of the time since the last spike; oxytocin neurons show
a constant hazard after a postspike interval (refractory period) of
about 50 msec, implying that after this there are no detectable
effects of an individual spike upon subsequent neuronal excit-
ability (15). Ratios of peak early (0.07-sec interspike interval)
to mean late (0.2- to 0.3-sec interspike intervals) hazards were
calculated before and after secretin administration to seek
change in the hazard plot as an indicator of altered excitability.
Thebasal firing rate of neuronswas recorded for 10min, after
which the rats were injected with iv CCK (sulfated cholecysto-
kininoctapeptide; 25g/kg;TocrisBioscience,Bristol,UK):oxy-
tocin neurons are transiently excited by CCKwhereas vasopressin
neurons aremostly transiently inhibited or are unaffected (9). Then
secretin (Tocris Bioscience) was administered iv at doses of 0.01,
0.1, or 1 g in 100 l normal saline. Vasopressin neurons were
studied using a single dose of secretin (0.1 g/rat) and responses
were compared with responses to iv CCK (25 g/kg).
To study the involvement of noradrenergic inputs, benox-
athian hydrochloride (Sigma, Dorset, UK), dissolved in artificial
cerebrospinal fluid [aCSF; composition: NaCl, 138 mM; KCl,
3.36mM;NaHCO3, 9.52mM;Na2HPO4 2H2O, 0.49mM; urea,
2.16 mM, CaCl2, 1.26 mM; MgCl2 6H2O, 1.18 mM (pH: 7.2);
300 mOsm], was infused i.c.v. (8 g/l min1), and the re-
sponses to secretin before and during the infusion were com-
pared. In further experiments, benoxathian was microdialyzed
(2 mM) onto the ventral surface of the SON.
Firing rates were averaged in 30-sec bins. For nonphasic oxy-
tocin and vasopressin neurons, the mean change in firing rate
(spikes/sec) was calculated for each 30-sec bin from the basal
activity (over 10 min) and activity after each injection. Phasic
firingpatternswere evaluatedby calculating the activity quotient
(the ratio of period active to total period), the frequency within
bursts (meannumber of spikes per burst overmeanburst length),
and the mean interburst interval.
Blood sampling
The left femoral vein was cannulated and connected to a sy-
ringe containing heparinized 0.9% saline (50 U/ml) in urethane-
anesthetized rats. At least 2 h later, a basal blood sample (0.3ml)
was taken into a heparinized syringe (30 l of 50 U/ml heparin
in 0.9% saline), followed by a vehicle injection (saline; 100 l;
iv), followed by a second sample 5 min later; withdrawn blood
was immediately replaced with an equivalent volume of sterile
0.9% saline, iv. Samples were collected 5, 10, and 25 min after
0.1g iv secretin and 5 and 10min after 1g iv secretin. Plasma
was separated and stored at 20 C until assayed.
Plasma oxytocin RIA
Thismethodwas adapted from that ofHiguchi et al. (17). The
primary antibody THF-3 (rabbit anti-oxytocin), kindly supplied
by Takashi Higuchi (University of Fukui, Fukui, Japan), was
diluted to a final concentration of 1:200,000 in RIA buffer and
added to tubes containing standard oxytocin (National Institute
for Biological Standards andControls,Hertfordshire, UK; range
2.4–2500pg/ml; in triplicate) or test samples (induplicate).After
24 h incubation at 4 C, radioiodinated oxytocin (125I, 3.7 KBq/
ml, 50 l; PerkinElmer, Life and Analytical Sciences, Bucking-
hamshire, UK) was added to all of the tubes. After 48-h incuba-
tion at 4C, a donkey antirabbit antibody (IDS Ltd., Boldon, UK)
at a dilution of 1:25 in assay buffer was added and incubated
overnight at 4 C. The following day, the antigen-antibody com-
2682 Velmurugan et al. Secretin Excites SON Neurons via NA Pathways Endocrinology, June 2010, 151(6):2681–2688
plex was precipitated by adding standardized Pansorbin cells
diluted to 1:25 in assay buffer. Radioactivity of the precipitate
was measured with a -counter (Wizard 1470 Automatic 
Counter, PerkinElmer, Life and Analytical Sciences) and un-
knownoxytocin concentrationswere readdirectly fromthe stan-
dard curve constructed automatically by the integrated data
analysis software (Wizard). The sensitivity of the assay was 2.4
pg/ml, and the intraassay variation was less than 15%.
Intracerebroventricular cannulation
A guide cannula (22 G; Bilaney Consultants Ltd., Kent, UK)
was positioned 1.6 mm lateral and 0.6 mm caudal to bregma
with its tip 3.5mmbelow the skull surface in
urethane anesthetized rats. A 28-G internal
cannula (Bilaney Consultants Ltd.) that
projected 1 mm below the tip of the guide
cannula was used for administration of
benoxathian into the right lateral cerebral
ventricle (i.c.v.).
In vivo microdialysis
As described above, rats were anesthe-
tized and the ventral surface of the brainwas
exposed. A U-shaped microdialysis probe
was prepared in house (membrane length 2
mm; inner diameter 200 m; mean pore di-
ameter: 4–6 nm; Cuprophan RC55, Mem-
brana, GmBH, Wuppertal, Germany). The
loop of the probewas positioned on the ven-
tral surface of the SON after opening the
meninges. The recording electrode was po-
sitioned within the loop (18). The SONwas
microdialyzed at 3 l/min with aCSF or
benoxathian (2 mM in aCSF) from a mi-
crosyringe mounted on a slow infusion
pump.
Statistical analysis
Data are shown as means  SEM. Statis-
tical tests were performed with SigmaStat
software version 3.10 (Systat Software Inc.,
London,UK).Datawere analyzed by paired
t test, t test, or one-way or two-way
ANOVA followed by appropriate post hoc
pairwise tests or one-way repeated mea-
sures (RM) ANOVA as appropriate. The
significance level for all statistics was set
at P  0.05.
Results
In initial studies (not shown), we used
doses of secretin similar to those that
have been used previously (5 and 10g/
rat; i.v.) (3, 4); these doses elicited
strong and prolonged excitatory re-
sponses in SONoxytocin and vasopres-
sin neurons, so we gradually reduced
the dose in subsequent experiments, un-
til we found that doses below 0.01 g iv were not consis-
tently effective.
Effect of secretin on oxytocin neurons
In the range 0.01–1 g iv, secretin dose dependently
increased the firing rate of SON oxytocin neurons (Fig. 1,
A and B; F  17.5, degrees of freedom  2, P  0.001,
one-wayANOVA).An increase in firing ratewasapparent
within about 30 sec, reaching a maximumwithin about 2
min and gradually subsiding to the basal firing rate by
FIG. 1. Effect of secretin on SON oxytocin neurons. Extracellular recordings of firing rates in
urethane-anesthetized female rats. A, Dose-dependent responses of oxytocin neurons to
increasing doses per rat of iv secretin at 1 g: n  3; 0.1 g: n  26 (all cells in this dose-
effect and subsequent experiments); and 0.01 g: n  4. Data are group means  SEM; n 
number of cells/rats. *, P  0.001, one-way ANOVA, 0–10 min postsecretin among groups;
pre- vs. 0–10 min postsecretin within the 1 g group: P  0.04, paired t test; pre- vs. 0–10
min postsecretin within the 0.1 g group: P  0.001, paired t test. B, Representative dose-
dependent responses of an oxytocin neuron to secretin. CCK (25 g/kg) and 0.1 g, 0.5 g,
and 1 g secretin were given iv as indicated by the arrows. C, Interspike interval histograms
of neurons shown in A (secretin 0.1 g): *, P  0.001, paired t test, incidence of interspike
intervals less than 0.5 sec 0–10 min after secretin vs. 10 min before secretin (n  26).
The descending slope of the histogram was fitted well with an exponential curve (y 
177.56e6.2398x) that characterizes oxytocin neurons (inset); r2  0.996. D, Hazard analysis of
firing of neurons shown in A (0.1 g; n  26). Despite a significant positive shift in the
hazard plot (P  0.001, Wilcoxon signed rank test), the profile of activity-dependent changes
in excitability was similar before and after secretin.
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20–30 min. Cells fired continuously throughout activa-
tion, with no change in the modal interspike interval (Fig.
1C). There was a significant positive shift in the hazard
function after secretin (Fig. 1D; P  0.001, Wilcoxon
signed rank test) with no change in its overall shape, as
indicated by the lack of change in the ratio of peak early
(0.07 sec) to mean late (0.2–0.3 sec) hazard 10 min
before (1.13 0.08) and after (1.09 0.08) secretin (P
0.7,Wilcoxon signed rank test). There was no correlation
between basal firing rate and the increase in the firing rate
(r2 0.0026). In parallel with the increase in the electrical
activity of SON oxytocin neurons, plasma oxytocin con-
centration was significantly and dose-dependently in-
creased (Fig. 2).
Response of oxytocin neurons to secretin and CCK
Secretin, even at a low dose (0.1 g/rat; 33 pmol), was
more potent than CCK (7.5 g; 6600 pmol; Fig. 3A; P
0.001, t test). The recovery phase of firing rate after ex-
citation induced by secretin or CCK was fitted well by
monoexponential curves (Fig. 3B) of the form R(t)  R0
et where R(t) is the rate at time t after the peak and R0 is
the rate at the peak of excitation;  is the decay constant.
The half-life for the recovery phase was calculated as t1/2
  logn2 where  (tau) is 1/. Half-life estimates for cir-
culating secretin range from1.5–5min (19, 20). Estimated
plasma concentrations (assuming distribution in ECF, 60
ml), for a half-life of 5 min (19), immediately and 10 min
after injectionof100ng secretinwere1700and425pg/ml;
for a half-life of 1.5 min (20), estimated plasma concen-
tration was approximately 400 pg/ml at 5 min, and less
than 100 pg/ml by 10 min. These values are in or near the
physiological range, 70 pg/ml (basal) to 730 pg/ml (during
5 d salt loading) (21). Oxytocin neurones were consis-
tently still strongly excited at 5–10min after secretin (100
ng) injection (Fig. 3), when secretin concentration was in
or near this physiological range.
Effect of secretin on vasopressin neurons
The responses of the two types of vasopressin neuron,
continuous and phasic, are described separately. In re-
sponse to secretin, 14 of 21 nonphasic vasopressin neu-
rons were excited, six were inhibited and one did not re-
spond; the overall response of this population to secretin
was not significant (Fig. 4A; P  0.2, paired t test). By
contrast, in response to CCK, 23 of 30 nonphasic vaso-
pressin neuronswere inhibited and seven did not respond;
the overall population response was a significant inhibi-
tion (Fig. 4A; P  0.001, Wilcoxon signed rank test).
Systemic administration of secretin excited each of six
phasic vasopressin neurons tested,whereasCCK inhibited
each of them. Secretin significantly increased and CCK
significantly decreased the activity quotient of these neu-
FIG. 2. Effect of systemic administration of secretin on systemic
oxytocin release in urethane-anesthetized female rats. Plasma oxytocin
concentration: A basal sample (B) was collected 2 h after jugular
cannulation; a sample (V) was taken 5 min after vehicle (100 l normal
saline; iv). Subsequently, samples were collected 5, 10, and 25 min
after iv administration of 0.1 g secretin and 5 and 10 min after
1 g secretin. Values are group means  SEM; n  6 rats per group.
*, P  0.05 (0.1 g secretin) and P  0.001 (1 g secretin), one-way
RM ANOVA, vs. basal and vehicle control. #, P  0.001, one-way RM
ANOVA, vs. 5 and 10 min after 0.1 g secretin. FIG. 3. Comparison of secretin and CCK-induced oxytocin neuron
responses in urethane-anesthetized female rats. A, Effect of secretin
(0.1 g/rat; iv) on the electrical activity of SON oxytocin neurons
compared with the CCK-induced (25 g/kg; iv) excitatory response;
values are group means  SEM. Group numbers are: secretin: n  26
neurons/rats; CCK: n  45 neurons/rats. *, P  0.001, t test, secretin
vs. CCK 0–10 min after administration between the groups. Pre- vs.
0–10 min postsecretin within the group: P  0.001, paired t test; pre-
vs. 0–10 min post-CCK within the group: P  0.001, Wilcoxon signed
rank test. B, The change in firing rate fitted to exponential curves.
Equation for secretin: y  2.2521e0.1353x; equation for CCK: y 
1.6231e0.1829x. r2 values of 0.95 and 0.89 for secretin and CCK,
respectively, indicate a good fit. The half-lives calculated from
exponential decreases in the firing rate are 5.1 and 3.8 min,
respectively, for secretin and CCK.
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rons (Fig. 4B). Secretin significantly decreased the mean
interburst interval (P 0.01, Wilcoxon signed rank test),
whereas CCK did not alter the interburst interval, but
there was no significant difference between secretin and
CCK treatment (P  0.4, t test). There was no change in
the mode of the interspike interval distribution (Fig. 4C)
after secretin.Therewas apositive shift in the hazard func-
tion after secretin (Fig. 4D; P  0.001, Wilcoxon signed
rank test) with no change in its overall shape.
Effect of i.c.v. benoxathian on secretin-induced
excitation of oxytocin neurons
In control conditions, repeated injections of secretin
(0.1 g/rat) produced similar responses with each injec-
tion, in three oxytocin neurons (e.g. Fig. 5A) and seven
vasopressin neurons tested (e.g. Fig. 5, B and D). In sep-
arate experiments, we then tested the effects of i.c.v.
benoxathian infusion on responses to this dose of secretin.
Six oxytocin neurons were studied during i.c.v. benox-
athian infusion, which reduced their basal firing rate of
5.7  1.05 spikes/sec to 2.2  0.9
spikes/sec (P 0.03, paired t test). The
secretin-induced excitatory response
was suppressed in all six neurons by
i.c.v. benoxathian; responses to iv CCK
were similarly blocked (Fig. 5C). Before
benoxathian, secretin increased the fir-
ing rate by 1.6  0.1 spikes/sec (P 
0.001, paired t test); duringbenoxathian
infusion, secretin had no effect (Fig. 5E;
P 0.7, Wilcoxon signed rank test).
Effect of i.c.v. benoxathian on
secretin-induced excitation of
vasopressin neurons
Benoxathian i.c.v. infusion inhibited
three of four phasic vasopressin neu-
rons within 20 min after the infusion
was begun, and during benoxathian in-
fusion, therewas no effect of secretin on
any of these three cells (e.g. Fig. 5D).
After stopping the infusion, the cells
gradually recovered their basal activity,
but we did not see a recovery of the re-
sponse to secretin within the recording
period.
Effect of benoxathian
microdialysis on secretin-induced
excitation of oxytocin neurons
Three oxytocin neurons were tested
during benoxathian microdialysis onto
the SON. Benoxathian microdialysis
alone did not significantly reduce the basal firing rate (av-
erage 2.5 0.6 spikes/sec before and 1.7 0.5 spikes/sec
during benoxathian, P  0.1, paired t test; the evident
reduction was similar to a previous finding) (22) but at-
tenuated the secretin-induced excitatory response in all
three cells. During vehicle microdialysis, the firing rate
was increased by 1.6  0.3 spikes/sec at 2 min after se-
cretin, whereas during benoxathian microdialysis, the fir-
ing rate was increased by only 0.6 0.1 spikes/sec at the
same time point (Fig. 5F; P 0.03, paired t-test, between
vehicle and benoxathian).
Discussion
Here we show that near-physiological systemic doses of
secretin excited SONoxytocinneurons and increasedoxy-
tocin secretion. The excitatory action of secretin was sim-
ilar to the response to CCK, but secretin wasmore potent.
The effect of secretin on SON vasopressin neurons was
FIG. 4. Effect of systemic administration of secretin (0.1 g; iv) and CCK (25 g/kg; iv) on
the firing rate of vasopressin neurons in urethane-anesthetized female rats. Values are group
means  SEM. A, Nonphasic vasopressin neurons. Group numbers are: secretin: n  21 cells/
rats; CCK: n  30 cells/rats. CCK inhibited firing and secretin excited firing: *, P  0.001, t
test, 0–5 min after secretin vs. CCK. B, Phasic vasopressin neurons: Activity quotient. Group
numbers are: secretin: n  11 cells/rats; CCK: n  7 cells/rats. Secretin was excitatory and
CCK was inhibitory; *, P  0.02, paired t test, pre- vs. 0–5 min postsecretin; #, P  0.02,
paired t test, pre- vs. 0–5 min post-CCK. , P  0.004, Kruskal-Wallis one-way ANOVA on
ranks, secretin vs. CCK response. C, Interspike interval histogram: incidence of interspike
intervals less than 0.5 sec 0–10 min after secretin (0.1 g) vs. 10-min basal period in
vasopressin neurons (combined histogram for phasic and nonphasic neurons; n  34). There
was no change in the incidence after secretin: P  0.2, paired t test. Inset, The distal tail of
the descending slope of the histogram fitted an exponential curve (y  237.29e7.2707x); r2
value of 0.96 indicates a good fit. However, intervals less than 0.2 sec did not fit: this
characterizes vasopressin neurons. D, Hazard analysis. There was a significant positive shift in
the hazard plot after secretin (0.1 g) administration (P  0.001, Wilcoxon signed rank test);
however, the profile of activity-dependent changes in excitability was similar before and after
secretin.
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predominantly excitatory, unlike CCK,
which was inhibitory. Blockade of the
effects of secretinbybenoxathian, given
by i.c.v. infusion or by microdialysis
onto the SON, indicates that noradren-
ergic pathways are involved in the se-
cretin-induced excitation of SON neu-
rons, as previously found for CCK
actions.
Previous studies have found that iv
secretin (40 g/kg) and i.c.v. secretin
(1–10 g) induce Fos in SON oxytocin
neurones (4, 23). However, the present
study shows that iv doses as low as
0.1–1 g significantly excite SON oxy-
tocin and vasopressin neurons, and in-
duce oxytocin secretion. From the re-
sponses of oxytocin neurons to secretin
and CCK, it appears that secretin is far
more potent thanCCK. The secretin in-
jection given in this study contained ap-
proximately200-fold fewermolesof se-
cretin (33 pmol) than the CCK (6.6
nmol) injection, and the iv dose of 0.1
g used in the present study is the low-
est systemic dose reported to have cen-
tral effects.
The magnocellular neurons of the
SON all express either oxytocin or va-
sopressin. They also express, in much
lower amounts, a profusion of other
peptides including many appetite-re-
lated peptides, including apelin, co-
caine and amphetamine regulated tran-
script, CCK, dynorphin, galanin, and
neuropeptide Y, together with their
cognate receptors (24).Most recently, it
has been shown that vasopressin cells
also express secretin and its receptor,
and that at high concentrations (100
nM) secretin can stimulate vasopressin
release from the isolated SON, and
i.c.v. administration of 0.45g secretin
can cause vasopressin release into the
circulation (21).Thus, secretin clearly is
capable of directly activating vasopres-
sin cells. However, in the present study
the effects of lower doses of secretin
given systemically (0.1g iv vs. 0.45g
i.c.v.) probably did not involve direct
effects on the SON neurons as the ef-
fects were abolished by i.c.v. benox-
athian. This finding is consistent with
FIG. 5. Effect of benoxathian i.c.v. infusion on secretin-induced responses of oxytocin and
vasopressin neurons in urethane-anesthetized female rats. Benoxathian infusion rate was 8 g/l
min1. The excitatory response to secretin (0.1 g/rat; iv) before benoxathian i.c.v. administration
was compared with the response during benoxathian administration. A and B, Representative
recordings of oxytocin and vasopressin neuron responses to repeated injections of secretin (0.1
g; iv) 38 and 40 min apart, respectively. Similar responses to the repeated dose of secretin ruled
out receptor desensitization. C, Representative recording of the effect of i.c.v. benoxathian
infusion on secretin-induced responses in a SON oxytocin neuron. CCK (25 g/kg; iv) was given
before (CCK1; to identify the cell as an oxytocin neuron from the excitatory response) and during
(CCK2) benoxathian infusion. Secretin (0.1 g; iv) was given before (1), during the infusion [(2)
and (3)], and after stopping benoxathian infusion (4). Benoxathian inhibited basal firing rate and
blocked CCK and secretin-induced responses; a response to secretin returned after benoxathian
infusion was stopped. D, Responses of a vasopressin neuron to secretin during benoxathian
infusion (8 g/l min1; i.c.v.; black bar). Secretin (0.1 g; i.v, arrows) was given before [(1) and
(2)], during [(3) and (4)], and after the infusion (5). Secretin given before the infusion increased the
activity quotient [secretin (1): from 0.07 to 0.38; secretin (2): from 0.28 to 0.43] and the
frequency within bursts [secretin (1): from 4.49 to 4.78 spikes/sec; secretin (2): from 4.63 to 5.73
spikes/sec] and decreased the mean interburst interval [secretin (1): from 69.6 to 34.6 sec; secretin
(2): not calculated as only one burst occurred during the basal 5 min period]. Secretin (3) given 23
min after starting the infusion also elicited an excitatory response, but secretin (4) given 58 min
after starting the infusion had no effect. The cell started to regain activity from 30 min after
stopping the benoxathian infusion. Secretin (5) given 120 min after stopping the infusion elicited
a slight excitatory response (activity quotient increased from 0.03 to 0.18 and frequency within
bursts increased from 0.94 to 1.52 spikes/sec). E, Effects of i.c.v. benoxathian on oxytocin
neurons. Values are group mean SEM; n 6 cells/ rats. Pre- vs. 0–10 min postsecretin before
benoxathian infusion: P 0.001, paired t test; pre- vs. 0–10 min postsecretin during benoxathian
infusion: P 0.7, Wilcoxon signed rank test; *, P 0.006, 0–5 min response to secretin before
vs. during benoxathian infusion, t test. F, Responses of oxytocin neurons to secretin during
benoxathian microdialysis: benoxathian was microdialyzed (2 mM; 3 l/min) onto the ventral
surface of the SON; n 3 cells/rats. Pre- vs. 0–10 min postsecretin during vehicle microdialysis:
P 0.03, paired t test; pre vs. 0–10 min postsecretin during benoxathian: P 0.1, paired t test;
0- to 5-min response to secretin during vehicle vs. benoxathian, *, P 0.03, t test.
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the interpretation that the physiological actions of circu-
lating secretin are on the afferent vagal nerve endings,
which signal to the hypothalamus via noradrenergic path-
ways from the caudal brain stem. This conclusion is sup-
ported by finding that the half-lives of change in firing rate
after administration of secretin (5.1 min) and CCK (3.8
min) corresponded with the estimated respective circulat-
ing half-lives of secretin (1.5 to 5 2 min in rats) (19, 20)
and CCK (1.5–3 min, measured in dogs) (25).
Interestingly, systemic secretin predominantly excited
vasopressin neurons, in striking contrast with the actions
of CCK, which either inhibits or has no effect on them
(9–11). The passive movement of water from plasma into
the intestinal lumen after secretin-induced exocrine pan-
creatic secretion of HCO3
 results in plasma hyperosmo-
lality and stimulates vasopressin release (26, 27). How-
ever, the rapid effects of secretin on vasopressin neurons
suggest that an additional, more direct, secretin-induced
activation is possible for SON vasopressin neurons. Both
secretin andCCK transiently increase blood pressure after
injection (28–30), so the activation of vasopressin neu-
rons by secretin is not a consequence of decreased blood
pressure.
Systemic secretin activates vagal afferents (6) and de-
polarizes neurons in the NTS (4). Subdiaphragmatic va-
gotomyabolishesFos expression inducedby secretin in the
NTS, but it was maintained in the area postrema (AP) (4)
suggesting that secretin may act directly on the AP neu-
rons. The SON receives excitatory noradrenergic projec-
tions from the NTS. The AP also has efferent projections
to the SONvia theA1 cell group (31, 32). TheAPandNTS
have reciprocal connections; hence, afferent input to the
AP may be relayed first to the NTS and then conveyed to
the SON or vice versa (33). Thus, the mode of action of
systemic secretin might be either direct on secretin recep-
tors on the SONneurons (5),whichwould require secretin
crossing the blood-brain barrier, or indirect through ac-
tivating vagal afferents and subsequently the brain stem
nuclei. Central infusion of benoxathian significantly at-
tenuated the basal firing and secretin-induced excitation
of oxytocin neurons indicating that central noradrenergic
pathways mediate the secretin-induced excitation of oxy-
tocin neurons via -1 adrenoceptors. A similar inference
can be drawn for vasopressin neurons, as i.c.v. benox-
athian also abolished secretin-induced excitation of vaso-
pressin neurons.
Systemic administration of CCK activates gastric vagal
afferents, resulting in the activation of NTS neurons,
which then excites SON oxytocin neurons via excitatory
noradrenergic projections from theNTS (9, 10). Although
the findings for oxytocin neurons are consistent with ac-
tions of circulating secretin and CCK via a noradrenergic
projection from the NTS, the opposite actions of iv secre-
tin (excitatory) and CCK (inhibitory) on vasopressin neu-
rons would seem not to be explained by such a possibly
common pathway.
Secretin, oxytocin, and vasopressin have intertwined
regulatory roles in gastric motility, water and electrolyte
homeostasis, and energy homeostasis (7, 24, 34–38). The
excitation of SON oxytocin and vasopressin neurons by
near-physiological levels of secretin in this study suggests
that some physiological effects of secretin might be medi-
ated through secretion of these neurohypophysial hor-
mones. A physiological role of the endocrine secretin sig-
nal that foodhas entered the small intestinemaybe that the
stimulation of oxytocin and vasopressin secretion leads to
excretion of ingested salt and conservation of water, after
water movement into the intestine, hence maintaining
homeostasis.
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